Jake Turrentine, MD
Dermatology · Hickory, NCNPI 1386934933
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $142,520 of the $154,112 with a category attached, or 92.5%. Sun Pharmaceutical Industries Inc. accounts for 74.6% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $55,519, more than ten times the $552 reported in 2019. Among dermatology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $806.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$115K
- Galderma Laboratories, L.p.$28K
- AbbVie$10K
- Biofrontera Inc.$478
- Pfizer$256
- Johnson & Johnson$232
- plus $738 from 10 others
Across 32 payments — averaging $7407.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$92K
- Amgen$62K
- Eli Lilly$28K
- Sun Pharmaceutical Industries Inc.$26K
- E.r. Squibb & Sons, L.L.C.$16K
- Pfizer$12K
What the payments were for
- Speaking & faculty fees$142,52092%
- Travel & lodging$7,5315%
- Food & beverage$3,6412%
- Education$4210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 70 | $115,017 |
| Galderma Laboratories, L.p. | 27 | $27,583 |
| AbbVie | 31 | $9,808 |
| Biofrontera Inc. | 2 | $478 |
| Pfizer | 23 | $256 |
| Johnson & Johnson | 6 | $232 |
| E.r. Squibb & Sons, L.L.C. | 8 | $203 |
| LEO Pharma Inc. | 6 | $133 |
| Novartis | 5 | $102 |
| Amgen | 4 | $77 |
| Strata Skin Sciences, Inc. | 3 | $75 |
| UCB, Inc. | 1 | $41 |
| Sanofi | 1 | $41 |
| Organon | 2 | $29 |
| Krystal Biotech Inc | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILUMYA$113,798
- NEMLUVIO$27,421
- Rinvoq$9,367
- AMELUZ$478
- BF-RhodoLED$478
How this compares
$154,112 in reported general payments places this provider in the 95th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 18 | $370,746 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 26 | $192,642 |
| Dupixent PenDupilumab | 31 | $130,792 |
| Humira PenAdalimumab | 11 | $74,496 |
| OtezlaApremilast | 12 | $57,433 |
| Dupixent SyringeDupilumab | 12 | $44,361 |
| Clobetasol Propionate | 261 | $11,470 |
| Doxycycline Hyclate | 190 | $4,881 |
| Tacrolimus | 31 | $4,166 |
| Fluorouracil | 49 | $3,492 |
| Metronidazole | 55 | $2,850 |
| Ketoconazole | 183 | $2,771 |
| Mycophenolate Mofetil | 22 | $1,701 |
| Triamcinolone Acetonide | 120 | $1,422 |
| Calcipotriene | 11 | $1,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $77 | $57,43312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 475 dermatology providers in North Carolina.
Other dermatology in Hickory
- George MagelHickory$554K
- Steven FeldmanWinston Salem$3.4M
- Nicole SeminaraHuntersville$1.4M
- Andrew LeeElkin$702K
- Christopher SayedChapel Hill$690K
- William HooverConcord$594K
- Patrick McElgunnCharlotte$565K
- Muneeb ShahClinton$451K
- John SoderbergCary$398K
- Rosalyn GeorgeWilmington$346K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.